DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial

被引：11

作者：

Klempner, Samuel J.

Chao, Joseph

Uronis, Hope Elizabeth

Sirard, Cynthia A.

Kagey, Michael

Baum, Jason

Song, James

Wang, Jin

Kim, In-Ho

Lee, Keun Wook

Oh, Do-Youn

Sonbol, Bassam Bassam

Wainberg, Zev A.

Ajani, Jaffer A.

机构：

[1] Angeles Clin & Res Inst, Los Angeles, CA USA

[2] City Hope Comprehens Canc Ctr, Duarte, CA USA

[3] Duke Univ, Durham, NC USA

[4] HeathCare Pharmaceut Inc, Cambridge, MA USA

[5] Leap Therapeut Inc, Cambridge, MA USA

[6] BeiGene, Beijing, Peoples R China

[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[9] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[10] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med,Canc Res Inst, Seoul, South Korea

[11] Mayo Clin Arizona Phoenix, Div Hematol Oncol, Canc Ctr, Phoenix, AZ USA

[12] UCLA Med Ctr Santa Monica, Santa Monica, CA USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

292

引用

页数：4